“We work systematically to strengthen our core business by delivering growth through the introduction of new products in existing markets and expanding products to new geographies. We have started and will continue the tedious process to increase company value by owning new products and brands. As a third step, we have been and will actively continue to source and evaluate M&A opportunities to deliver sustainable growth with the objective of building Navamedic to a leading Nordic pharmaceutical company with a footprint in North Europe and other selected countries,” says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.
Stock exchange news
Navamedic ASA: Notice of Annual General Meeting
The annual general meeting of Navamedic ASA (OSE: NAVA) will be held on Thursday, June 3rd 2021 at 13:00 (CET) Read more
Navamedic ASA: Q1 2021 financial
“In the first quarter of 2021, we continued to deliver growth in our underlying portfolio. The rapid growth of specialty Read more
Navamedic ASA: Icepharma new distributor of antibiotics to the Icelandic market
As announced on 4 August 2020, Navamedic completed the acquisition of marketing authorisations in the Nordics for a portfolio of Read more
Meet us at exhibitions and fairs
Unfortunately, due to Covid-19. Exhibitions are postponed or cancelled until further notice.